Cell & Gene The Podcast: Inside BlueRock Therapeutics’ Parkinson’s Disease Trial

Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company’s phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells’ (iPSCs) play in the trial, and they also discuss the company’s investigational cell therapy, bemdaneprocel.

Click here to listen.

Related News

Research Insights

How new modalities could evolve the treatment of Parkinson’s disease

November 13, 2024
Research Insights

Parkinson’s in Perspective: An Interview with Vikas Chinnan

October 2, 2024
Press Releases

BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months

September 27, 2024
Research Insights

How new modalities could evolve the treatment of Parkinson’s disease

November 13, 2024
Research Insights

Parkinson’s in Perspective: An Interview with Vikas Chinnan

October 2, 2024
Press Releases

BlueRock Therapeutics’ investigational cell therapy bemdaneprocel for Parkinson’s disease shows positive data at 24-months

September 27, 2024